Target intelligence / Profile preview

Pseudomonas aeruginosa elastase (LasB) (LasB)

Target
LasB
Molecular classification
Enzyme, Metalloprotease, Zinc metallopeptidase, M4 family protease
01

Overview

Pseudomonas aeruginosa elastase, commonly referred to as LasB or pseudolysin, is a potent extracellular zinc-metalloprotease and a primary virulence factor of the opportunistic pathogen Pseudomonas aeruginosa (UniProt P06132). It functions by degrading a broad spectrum of host proteins, including elastin, collagen, laminin, and various immune system components such as cytokines, complement factors, and immunoglobulins (PMID: 25151270). This enzymatic activity facilitates bacterial attachment, tissue penetration, and the neutralization of host immune responses, particularly in chronic infections like those found in cystic fibrosis and non-healing wounds (PMID: 21854357). LasB also contributes to the structural integrity of bacterial biofilms, making the pathogen more resistant to treatment. As an anti-virulence target, inhibiting LasB aims to disarm the bacteria rather than killing them directly, which may exert less selective pressure for the development of antibiotic resistance (PMID: 32692544). Current therapeutic strategies involve the design of small-molecule inhibitors that specifically bind the zinc-containing active site of the enzyme. These inhibitors are being explored to reduce tissue damage and enhance the efficacy of conventional antibiotics.

Other names
PseudolysinPseudomonas elastaseLasB proteaseZinc metalloendopeptidaseLasB metalloendopeptidase
02

Mechanism of action

Inhibition of the zinc-dependent catalytic activity of the enzyme to prevent degradation of host tissues and immune factors.

03

Biological functions

ProteolysisDegradation of host extracellular matrixImmune evasionBiofilm formationTissue invasion
04

Disease associations

InfectionCystic fibrosisPneumoniaChronic wound infectionKeratitis
05

Safety considerations

Cross-reactivity with human matrix metalloproteinases (MMPs)Potential for off-target effects on host zinc-dependent enzymesDelivery to intracellular or biofilm-protected bacteria
06

Interacting drugs

Galardin (GM6001)

4 more in the full profile.

07

Biomarkers

LasB activity levels in clinical samplesLasB protein concentration in sputumAnti-LasB antibody titers

Beyond the preview

Go deeper on Pseudomonas aeruginosa elastase (LasB) (LasB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pseudomonas aeruginosa elastase (LasB) (LasB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call